prmt-5-in-1

PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).

PRMT5-IN-14 is a PRMT5 inhibitor used to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

PRMT5-IN-13 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5).

PRMT5-IN-15, a PRMT5 inhibitor, has an IC50 value of 0.84 nM.

PRMT5-IN-11 demonstrates potent structure-dependent inhibition against the protein methyltransferase PRMT5:MEP50 complex at submicromolar concentrations.

PRMT5-IN-12 demonstrates significant inhibitory activity on PRMT5.

PRMT5-IN-10 exhibits promising structure-dependent inhibitory effect on the protein methyltransferase PRMT5:MEP50 complex.

PRMT5-IN-19 (Compound 41) is a potent, orally active PRMT5 inhibitor, exhibiting selectivity towards the SAM-binding pocket of PRMT5 with IC50 values of 23.9 nM (radioactive biochemical assay) and 47 nM (AlphaLISA assay). It effectively blocks methyltransferase activity and demonstrates high specificity against other PRMTs and PKMTs, exerting anti-proliferative effects through apoptosis induction and holding potential in cancer-related research [1].

PRMT5 IN-1 hydrochloride (compound 9) is a hemiacetalamine and a potent inhibitor of selective protein arginine methyltransferase 5 (PRMT5), exhibiting an inhibitory effect on PRMT5/MEP50 with an IC50 of 11 nM. Under physiological conditions, it can be converted to an aldehyde and reacts with C449 to form a covalent adduct.

PRMT5-IN-17 (Compound 6) is a PRMT5 inhibitor with antitumor activity; PRMT5, a protein arginine methyltransferase, is a novel anticancer target linked to epigenetic modifications.

PRMT5-IN-16 (Compound 20) is a PRMT5 inhibitor with antitumor effects, targeting the protein arginine methyltransferase PRMT5, which is a novel anti-tumor target associated with epigenetic modifications.

PRMT5-IN-18 (Compound 002) is a potent inhibitor of PRMT5, useful in studying PRMT5-mediated diseases such as tumors.